CD19
Synonyms
Differentiation antigen CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, CD19 Antigen, B-Lymphocyte Antigen CD19, CVID3, B4, Antigens, CD19, CD19, T-cell surface antigen Leu-12
Description
B-lymphocyte antigen CD19 functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. CD19 decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. CD19 activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca stores. And it is required for normal differentiation of B-1 cells, normal B cell differentiation and proliferation in response to antigen challenges, normal levels of serum immunoglobulins and for production of high-affinity antibodies in response to antigen challenge.
KO Status
RenMab: F0
RenLite: F0
Drug Information
Launched drugs: 9
Drugs in clinical trials: 181
Latest Research Phase: Approved
Drug Name
Code
Phase
Company
Indications
Clinical Trials
Tafasitamab
XmAb-5574, MOR-208, XENP-5574, MOR-00208
Approved
Xencor
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04824092
NCT04680052
NCT02763319
NCT01685008
NCT02639910
NCT04646395
NCT04974216
NCT04978584
NCT02399085
NCT01685021
NCT04882163
NCT04607772
NCT04809467
NCT04661007
NCT01161511
NCT04134936
NCT04300803
Intervention Type
Drug
Drug
Drug
Drug
Biological, Drug
Drug
Drug
Biological, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological
Drug
Biological
Indications
Non-Hodgkin Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Diffuse Large B-cell Lymphoma
DLBCL
Study Phase
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
N/A
Recruitment Status
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Not yet recruiting
Not yet recruiting
Active, not recruiting
Terminated
Withdrawn
Suspended
Recruiting
Recruiting
Completed
Active, not recruiting
Approved for marketing
CAR-20-19-22(Medical College of Wisconsin)
CAR-20-19-22
The Medical College Of Wisconsin Nonprofit
NCT Number
NCT05094206
Intervention Type
Biological
Indications
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
Axicabtagene ciloleucel
KTE-C19, KTE C19, FKC-876
Approved
Cabaret Biotech
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary mediastinal B cell lymphoma
NCT Number
NCT03391466
NCT04150913
NCT04531046
NCT03105336
NCT05041309
NCT02601313
NCT03761056
NCT04205838
NCT04359784
NCT04432506
NCT04002401
NCT04314843
NCT02625480
NCT02926833
NCT00924326
NCT04257578
NCT02348216
NCT03704298
NCT02614066
NCT04608487
NCT03624036
NCT05077527
NCT03153462
NCT04162756
NCT03642626
Intervention Type
Biological, Drug
Drug
Drug
Biological, Drug
Biological
Biological, Drug
Biological, Drug
Biological, Drug
Biological
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological
Biological, Drug
Drug
Indications
Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma; Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma; Mantle Cell
Relapsed/Refractory Diffuse Large B Cell Lymphoma; Relapsed/Refractory Primary Mediastinal B Cell Lymphoma; Relapsed/Refractory Transformed Follicular Lymphoma; Relapsed/Refractory High-Grade B-Cell Lymphoma
Study Phase
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
N/A
N/A
N/A
Recruitment Status
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Not yet recruiting
Active, not recruiting
Active, not recruiting
Suspended
Not yet recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Not yet recruiting
Approved for marketing
Approved for marketing
Recruiting
Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion, Czech Republic)
Institute of Hematology and Blood Transfusion, Czech Republic
Loncastuximab tesirine
ADCT-402
Approved
Adc Therapeutics
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04384484
NCT03589469
NCT04998669
NCT04699461
NCT03684694
NCT05053659
NCT02669017
NCT04974996
NCT03685344
NCT02669264
NCT04705454
Intervention Type
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological
Indications
Non-Hodgkin Lymphoma; Burkitt's Lymphoma; Chronic Lymphocytic Leukemia; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Marginal Zone; Waldenstrom Macroglobulinemia; Primary Mediastinal B-cell Lymphoma
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Study Phase
Phase 3
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
Recruitment Status
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Completed
Not yet recruiting
Terminated
Terminated
No longer available
Inebilizumab
16C4-aFuc, MEDI-551, MT-0551, VIB-0551
Approved
Duke University
Rejection of renal transplantation, Myasthenia Gravis, Lymphoma, B-Cell, Hematologic Neoplasms, Immunoglobulin G4-Related Disease, Scleroderma, Systemic, Lymphoma, Large B-Cell, Diffuse, Multiple Sclerosis, Neuromyelitis Optica, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04540497
NCT04524273
NCT02200770
NCT04174677
NCT01453205
NCT01466153
NCT03218163
NCT04372615
NCT02271945
NCT00983619
NCT01585766
NCT00946699
NCT01957579
Intervention Type
Other, Drug
Drug
Other, Drug
Drug
Procedure, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other, Biological
Drug
Indications
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Highly Sensitized Patients on Waiting List for Kidney Transplantation
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Relapsed/Refractory Aggressive B-cell Lymphomas
B-cell Malignancies; Cancer
Multiple Sclerosis, Relapsing Forms
Scleroderma
Blood Cancer; Advanced B Cell Malignancies
Study Phase
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Completed
Suspended
Completed
Completed
Terminated
Not yet recruiting
Completed
Completed
Completed
Completed
Completed
Relmacabtagene autoleucel
JWCAR-029
Approved
Suzhou Yaomingjunuo Biotechnology Co Ltd
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT04089215
NCT04718883
NCT03344367
NCT04812691
NCT03355859
Intervention Type
Biological
Biological
Biological
Biological
Biological
Indications
Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma; Follicular Lymphoma
Mantle Cell Lymphoma
Non Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
Non Hodgkin Lymphoma
Study Phase
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Tisagenlecleucel
LG-740, CART-19, CTL-019, CART-019
Approved
University Of Pennsylvania, Novartis Pharma Ag
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Plasmablastic Lymphoma, Leukemia, B-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT03628053
NCT04094311
NCT03123939
NCT03570892
NCT03027739
NCT04161118
NCT02030834
NCT02935543
NCT03568461
NCT04456023
NCT04225676
NCT02445248
NCT01747486
NCT02794246
NCT03610724
NCT04156659
NCT02167360
NCT02228096
NCT02030847
NCT03876769
NCT02435849
NCT01626495
NCT01551043
NCT02810223
NCT03876028
NCT03630159
NCT02135406
NCT01029366
NCT04134117
NCT05075603
NCT03101709
NCT02906371
NCT04890236
NCT02640209
NCT02476734
NCT02445222
NCT03642626
NCT03601442
Intervention Type
Biological, Drug
Biological
Biological
Drug
Biological
Drug
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Drug
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Biological, Drug
Biological, Drug
Biological
Biological
Biological
Drug
Biological, Drug
Biological, Drug
Biological, Drug
Biological
Other
Genetic
Drug
Biological
Indications
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Leukemia, Acute Lymphoblastic
Follicular Lymphoma
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
Multiple Myeloma
B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
B Cell Leukemia; B Cell Lymphoma
Acute Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Multiple Myeloma
Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Primary CNS Lymphoma; Refractory Primary CNS Lymphoma; Relapsed Primary CNS Lymphoma
B Cell Lymphoma
LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Study Phase
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
Recruitment Status
Withdrawn
Recruiting
Completed
Active, not recruiting
Recruiting
Recruiting
Completed
Terminated
Active, not recruiting
Not yet recruiting
Completed
Active, not recruiting
Completed
Terminated
Recruiting
Not yet recruiting
Withdrawn
Completed
Completed
Recruiting
Active, not recruiting
Completed
Terminated
Unknown status
Completed
Completed
Completed
Completed
Recruiting
Recruiting
Unknown status
Completed
Not yet recruiting
Terminated
Completed
Recruiting
Recruiting
Available
Lisocabtagene maraleucel (Celgene/Juno Therapeutics)
Liso-Cel, JCAR-017, JWCAR-029
Approved
Juno Therapeutics, Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute
Lymphoma, B-Cell, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoproliferative Disorders, Lymphoma, Non-Hodgkin, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03575351
NCT04245839
NCT03484702
NCT03483103
NCT03744676
NCT03331198
NCT03743246
NCT02028455
NCT03310619
NCT02631044
NCT03186118
NCT04400591
NCT03436771
Intervention Type
Drug, Genetic
Drug
Drug
Biological
Biological
Biological
Drug
Biological
Biological, Drug
Biological
Biological
Biological
Genetic
Indications
Lymphoma, Non-Hodgkin; Lymphoma, Nonhodgkin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
CD19+ Acute Leukemia
CD 19+ Acute Leukemia
Non Hodgkin Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma
Study Phase
Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
N/A
N/A
Recruitment Status
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Available
Terminated
Blinatumomab
MEDI-538, MT-103, BiTE-MT-103, bscCD19xCD3, AMG-103
Approved
Amgen Inc
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04506086
NCT04722848
NCT02101853
NCT04530565
NCT05029531
NCT02013167
NCT02393859
NCT02003222
NCT03914625
NCT04994717
NCT03643276
NCT03476239
NCT02910063
NCT03117751
NCT04554485
NCT03518112
NCT03982992
NCT02807883
NCT04546399
NCT02744768
NCT04329325
NCT01207388
NCT04334993
NCT02811679
NCT04044560
NCT03849651
NCT04746209
NCT02877303
NCT03709719
NCT02458014
NCT04785547
NCT04556084
NCT03109093
NCT03367299
NCT02997761
NCT03121534
NCT03523429
NCT03023878
NCT01209286
NCT01741792
NCT03480438
NCT02143414
NCT03263572
NCT02000427
NCT00560794
NCT02790515
NCT03298412
NCT03739814
NCT04827745
NCT03541083
NCT03931642
NCT04688983
NCT01466179
NCT04448834
NCT00676871
NCT03114865
NCT02412306
NCT03512405
NCT01471782
NCT01371630
NCT03160079
NCT03072771
NCT02961881
NCT02879695
NCT02568553
NCT03340766
NCT04524455
NCT00538096
NCT00274742
NCT04604691
NCT03751709
NCT03605589
NCT04521231
NCT03173430
NCT02187354
NCT04723342
NCT03318770
NCT03117621
Intervention Type
Drug
Drug
Procedure, Other, Biological, Radiation, Drug
Biological, Drug
Combination Product
Drug
Drug
Procedure, Other, Biological, Drug
Biological, Radiation, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other, Biological, Drug
Drug
Procedure, Drug
Biological, Radiation, Drug
Drug
Biological, Drug
Drug
Drug
Drug
Biological
Biological, Drug, Device
Drug, Device
Other, Biological, Drug
Drug
Other, Biological
Drug
Drug
Drug
Drug
Biological, Drug
Drug
Drug
Drug
Biological
Drug
Drug
Other, Biological, Drug
Biological, Drug
Drug
Biological
Biological, Drug, Device
Drug
Biological
Drug
Drug
Drug
Drug
Biological
Drug
Drug
Drug
Drug
Other, Biological
Biological
Other, Biological, Drug
Drug
Procedure, Drug
Drug
Biological
Biological, Drug
Drug
Drug
Drug
Biological
Drug
Other, Drug
Drug
Drug
Drug
Other, Drug
Drug
Drug
Indications
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); ALL, Adult; Philadelphia-Positive ALL
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
B-Cell Non Hodgkin Lymphoma
B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation; B-Cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia in Remission; Acute Lymphoblastic Leukemia, Adult
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
B-cell Acute Lymphoblastic Leukemia
Philadelphia-Negative ALL; High-Risk Cancer
Non-Hodgkin Lymphoma
B-cell Adult Acute Lymphoblastic Leukemia; Stem Cell Leukemia; Minimal Residual Disease
B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia, Adult B-Cell
ALL, Childhood; Minimal Residual Disease
B-cell Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia
Acute Lymphoid Leukemia; Philadelphia Chromosome-Negative B-Cell Precursor
Hematopoietic/Lymphoid Cancer; Richter's Transformation
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
High-risk Diffuse Large B-Cell Lymphoma
B-ALL
Diffuse Large B-cell Lymphoma
B-Precursor ALL
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia; t(9;22)
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myeloid Sarcoma; Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Myelodysplastic Syndrome (MDS); Non-Hodgkin Lymphoma (NHL)
High-risk Diffuse Large B-cell Lymphoma
ALL, Adult
Acute Lymphoblastic Leukemia, Adult
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia; B-cell Non Hodgkin Lymphoma; Pre B-Cell Acute Lymphoblastic Leukaemia
Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
CD19 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Pre-B Acute Lymphoblastic Leukemia
B-Cell Acute Lymphoblastic Leukemia, Adult
Diffuse Large B Cell Lymphoma
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin
Non-Hodgkin's Lymphoma, Relapsed
Pediatric ALL, B Cell; Minimal Residual Disease
Leukemia, B-cell; Lymphoma, B-Cell
Multiple Myeloma
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Study Phase
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Early Phase 1
N/A
N/A
N/A
N/A
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Recruiting
Not yet recruiting
Terminated
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Completed
Completed
Recruiting
Recruiting
Completed
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Completed
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Completed
Completed
Completed
Recruiting
Active, not recruiting
Recruiting
Completed
Completed
Recruiting
Terminated
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Completed
Suspended
Withdrawn
Recruiting
Completed
Recruiting
Completed
Recruiting
Recruiting
Active, not recruiting
Completed
Recruiting
Recruiting
Active, not recruiting
Recruiting
Withdrawn
Completed
Not yet recruiting
Recruiting
Withdrawn
Recruiting
Terminated
No longer available
Recruiting
Not yet recruiting
Recruiting
Brexucabtagene autoleucel
KTE-X19
Approved
Kite Pharma Inc
Lymphoma, Mantle-Cell
NCT Number
NCT04880434
NCT05041309
NCT02625480
NCT03624036
NCT04162756
Intervention Type
Biological, Drug
Biological
Biological, Drug
Biological, Drug
Biological, Drug
Indications
Study Phase
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
N/A
Recruitment Status
Recruiting
Not yet recruiting
Recruiting
Active, not recruiting
Approved for marketing
Anti-CD19 UCAR-T cell Therapy (Gracell Biotechnologies)
Gracell Biotechnology Ltd
NCT Number
NCT05105867
Intervention Type
Biological
Indications
Study Phase
Early Phase 1
Recruitment Status
Recruiting
CD19 CAR-T cell therapy (National University of Malaysia)
Phase 3 Clinical
National University Of Malaysia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03937544
Intervention Type
Biological, Drug
Indications
Relapsed B Acute Lymphoblastic Leukaemia; Refractory B Acute Lymphoblastic Leukaemia
Study Phase
Phase 2/Phase 3
Recruitment Status
Recruiting
Anti-CD19 CAR T-cell therapy (Sheba Medical Center)
Phase 3 Clinical
Chaim Sheba Medical Center At Tel Hashomer
Leukemia, Myeloid, Acute
NCT Number
NCT04257175
NCT02772198
Intervention Type
Biological
Biological
Indications
Acute Lymphoblastic Leukemia, B-precursor; Non-Hodgkin Lymphoma, B-cell
Study Phase
Phase 2/Phase 3
Phase 1/Phase 2
Recruitment Status
Recruiting
Recruiting
Obexelimab
AMG-729, XmAb-5871
Phase 3 Clinical
Xencor
Immunoglobulin G4-Related Disease, Arthritis, Rheumatoid, Autoimmune Diseases, Lupus Erythematosus, Systemic
NCT Number
NCT02725515
NCT02725476
NCT02867098
Intervention Type
Biological
Biological
Drug
Indications
Systemic Lupus Erythematosus
IgG4-RD
Healthy Volunteers
Study Phase
Phase 2
Phase 2
Phase 1
Recruitment Status
Completed
Completed
Completed
Anti-CD19 CAR T-cell therapy (Fujian Medical University)
Phase 3 Clinical
Fujian Medical University
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics)
CT-120
Phase 2 Clinical
Nanjing Iaso Biotherapeutics Co Ltd
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT05091541
Intervention Type
Drug
Indications
Study Phase
Phase 1/Phase 2
Recruitment Status
Not yet recruiting
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology)
SENL-B19
Phase 2 Clinical
Hebei Senlang Biological Technology Co Ltd
Leukemia, Lymphoma, B-Cell, Leukemia, B-Cell, Lymphoma
NCT Number
NCT03312205
NCT02963038
NCT03121625
NCT04792593
Intervention Type
Biological
Biological
Biological
Biological
Indications
Leukemia; Lymphoma; Multiple Myeloma of Bone (Diagnosis)
B-Cell Leukemia; B-Cell Lymphoma
Leukemia; Lymphoma
B-ALL
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
N/A
Recruitment Status
Recruiting
Recruiting
Recruiting
Recruiting
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing)
Phase 2 Clinical
Xuanwu Hospital Of Capital Medical University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03902197
Intervention Type
Biological
Indications
Acute Lymphoblastic Leukemia
Study Phase
Phase 2
Recruitment Status
Recruiting
IM19CAR-T
Phase 2 Clinical
Beijing Yimiao Medical Technology Co Ltd
Leukemia, Hematologic Neoplasms, Lymphoma, Non-Hodgkin
NCT Number
NCT03173417
NCT04440436
NCT03142646
NCT03344705
NCT03528421
NCT04336501
Intervention Type
Biological, Drug
Drug
Biological
Biological, Drug
Biological, Drug
Biological
Indications
Leukemia
NHL
Leukemia
Hematological Malignancies
Non Hodgkin Lymphoma
Leukemia
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
N/A
Recruitment Status
Completed
Recruiting
Unknown status
Recruiting
Unknown status
Recruiting
CD19/CD22 bispecific CAR-T (Zhejiang University)
Phase 2 Clinical
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04788472
Intervention Type
Drug
Indications
B-Cell Acute Lymphoblastic Leukemia, Adult
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
HuCART19
Phase 2 Clinical
National Cancer Institute, Kite Pharma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03792633
NCT03620058
NCT02659943
NCT02374333
Intervention Type
Biological
Biological
Biological, Drug
Biological
Indications
Lymphoma, B-Cell; Lymphoma, Non-hodgkins
Study Phase
Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Recruiting
Active, not recruiting
Active, not recruiting
Completed
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital)
Phase 2 Clinical
Shenzhen University General Hospital
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04723901
Intervention Type
Biological
Indications
Dual-target CAR-T Cells; B ALL; Relapse; Refractory B Acute Lymphoblastic Leukemia
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
CAR-T 19 cell therapy (University of Pennsylvania)
Phase 2 Clinical
University Of Pennsylvania
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04276870
Intervention Type
Biological
Indications
Study Phase
Phase 2
Recruitment Status
Active, not recruiting
Anti-CD19 CAR-T cell therapy (Uppsala University)
Phase 2 Clinical
Uppsala University
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03068416
Intervention Type
Biological
Indications
Study Phase
Phase 2
Recruitment Status
Completed
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid)
Phase 2 Clinical
Wuhan Bio-Raid Biotechnology
Hematologic Diseases, Lymphoma, B-Cell
Anti-CD19 CAR-T cell therapy (Sinobioway)
Phase 2 Clinical
Sinobioway Biomedicine Co Ltd
Lymphoma, Large B-Cell, Diffuse, Lymphoma
PBCAR-0191
PBCAR-0191
Phase 2 Clinical
Baxalta
Hematologic Neoplasms, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin
NCT Number
NCT04649112
Intervention Type
Genetic
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital)
Phase 2 Clinical
Pla General Hospital
Lymphoma, B-Cell
NCT Number
NCT04163302
Intervention Type
Biological
Indications
Lymphoma, B-Cell
Study Phase
Phase 2
Recruitment Status
Recruiting
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital)
Phase 2 Clinical
Pla General Hospital
Leukemia, Lymphoma, B-Cell
NCT Number
NCT03398967
Intervention Type
Biological
Indications
B Cell Leukemia; B Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
3rd-gen-CD19-CAR
3rd-gen-CD19-CAR
Phase 2 Clinical
Bluebird Bio
Lymphoma, B-Cell, Leukemia, B-Cell
CD19.CAR T Cells (University Hospital Heidelberg)
Phase 2 Clinical
University Of Heidelberg
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03676504
Intervention Type
Biological, Drug
Indications
Acute Lymphoblastic Leukemia, Adult; Acute Lymphoblastic Leukemia, Pediatric; Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
TI-1007
TI-1007
Phase 2 Clinical
Tianjin Timmune Biotech Inc
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT03720496
Intervention Type
Biological
Indications
Non-hodgkin Lymphoma,B Cell
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University)
Phase 2 Clinical
Suzhou University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03984968
NCT04846439
Intervention Type
Biological
Biological
Indications
Acute Lymphoblastic Leukemia, Adult B-Cell
Study Phase
Phase 2
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
Recruiting
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory)
Phase 2 Clinical
Bioray Laboraytories Inc
Leukemia
NCT Number
NCT03232619
NCT04213469
Intervention Type
Biological
Biological
Indications
Acute Leukemia
Study Phase
Phase 1/Phase 2
N/A
Recruitment Status
Completed
Recruiting
CAR-CD19 T cell therapy
Phase 2 Clinical
Carsgen Biomedicine (Shanghai) Co Ltd
Lymphoma, Non-Hodgkin
NCT Number
NCT03994913
NCT02933775
Intervention Type
Biological
Drug, Genetic
Indications
Refractory B-Cell Non-Hodgkin Lymphoma; Relapsed B-cell Non-Hodgkin Lymphoma
CD19 Positive Malignant B-cell Leukemia and Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Recruiting
Unknown status
CART-19 cells (Henan Hualong Biotechnology)
Phase 2 Clinical
Henan Hualong Biotechnology
Leukemia, Lymphoid
CD19 CAR-T cell therapy (Chongqing Precision Biotech)
Phase 2 Clinical
Chongqing Precision Biotechnology Co Ltd
Lymphoma, B-Cell, Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, B-Cell, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04271410
NCT04271800
Intervention Type
Biological
Biological
Indications
Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-cell; Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia; Lymphoma; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Recruitment Status
Recruiting
Recruiting
CLIC-1901 (Ottawa Hospital Research Institute)
CLIC-1901
Phase 2 Clinical
Ottawa Hospital Research Institute
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03765177
Intervention Type
Biological
Indications
Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics)
ICTCAR-014
Phase 2 Clinical
Innovative Cellular Therapeutics Co Ltd
Lymphoma, Non-Hodgkin
Anti-CD19 CAR T-cell therapy (Nanjing Medical University)
XLCART-001
Phase 2 Clinical
Nanjing Medical University
Lymphoma, B-Cell
CTL-119
CTL-119
Phase 2 Clinical
University Of Pennsylvania, Novartis Pharma Ag
Lymphoma, Large B-Cell, Diffuse, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03549442
Intervention Type
Combination Product
Indications
Study Phase
Phase 1
Recruitment Status
Active, not recruiting
GNR-084
GNR-084
Phase 2 Clinical
Generium Pharmaceuticals, Iontas
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04601584
Intervention Type
Biological
Indications
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
GTB-1550
DT-2219, OXS-1550, DT-2219ARL, IND-100780
Phase 2 Clinical
University Of Minnesota
Leukemia, Lymphoma, B-Cell
NCT Number
NCT02370160
NCT00889408
Intervention Type
Biological
Biological
Indications
Refractory B-Lineage Leukemia; Relapsed B-Lineage Leukemia; Refractory B-Lineage Lymphoma; Relapsed B-Lineage Lymphoma
Leukemia; Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Completed
Completed
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology)
Phase 2 Clinical
Shanghai Zhongshan Hospital, Hrain Biotechnology
Candidiasis, Vulvovaginal, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03720457
NCT03798509
Intervention Type
Drug
Drug
Indications
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine)
yinnuokati-19
Phase 2 Clinical
Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals)
BPX-401
Phase 2 Clinical
Bellicum Pharmaceuticals, Ospedale Pediatrico Bambino Gesu
Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma
NCT Number
NCT04787263
Intervention Type
Biological
Indications
Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; Primary Mediastinal Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital)
Phase 2 Clinical
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital
Leukemia
NCT Number
NCT00466531
Intervention Type
Biological, Drug
Indications
Study Phase
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
JCAR-015
JCAR-15, JCAR-015, 19-28z-T-Cells, 19-28z+ T cells, 19-28z CAR T cells
Phase 2 Clinical
Seattle Children'S Research Institute, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, Juno Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT02535364
NCT02973191
NCT01840566
NCT01044069
NCT01416974
NCT02813252
Intervention Type
Biological
Drug
Procedure, Biological, Drug
Biological
Biological, Drug
Genetic
Indications
Acute Lymphoblastic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-Hodgkin's Lymphoma
Leukemia; Acute Lymphoblastic Leukemia
Leukemia
Acute Lymphoblastic Leukemia
Study Phase
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
N/A
Recruitment Status
Terminated
Withdrawn
Active, not recruiting
Active, not recruiting
Completed
Active, not recruiting
Coltuximab ravtansine
SAR-3419, huB4-DM4
Phase 2 Clinical
Immunogen
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT01472887
NCT01470456
NCT01440179
NCT00549185
NCT00796731
Intervention Type
Drug
Drug
Drug
Drug
Drug
Indications
Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Acute Lymphocytic Leukaemia
Lymphoma; Non-Hodgkin
Lymphoma; Non-Hodgkin
Study Phase
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Terminated
Completed
Completed
PCAR-119 (PersonGen Biomedicine)
PCAR-119
Phase 2 Clinical
Leukemia, Lymphoma, Large B-Cell, Diffuse, Leukemia, Prolymphocytic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02892695
Intervention Type
Biological
Indications
Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; B-cell Prolymphocytic Leukemia; Diffuse Large Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Unknown status
Anti-CD19 CAR T cell therapy (Shanghai GeneChem)
Phase 2 Clinical
Shanghai Genechem Co Ltd
Lupus Erythematosus, Systemic, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, B-Cell
NCT Number
NCT02672501
NCT03030976
Intervention Type
Drug
Drug
Indications
Leukemia, B-Cell
Systemic Lupus Erythematosus (SLE)
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Unknown status
Unknown status
Anti-CD19 CAR-T cell therapy (Juventas)
CNCT19, CNCT-19, HY001
Phase 2 Clinical
Heyuan Biotechnology (Tianjin) Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04684147
NCT04586478
NCT04690192
NCT04230473
NCT04011293
Intervention Type
Biological
Biological
Biological, Drug
Biological
Biological
Indications
Relapsed or Refractory Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Large B-cell Lymphoma
Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Hematological Malignancies
Study Phase
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Early Phase 1
Recruitment Status
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy
GC-197
Phase 2 Clinical
Gracell Biotechnologies (Shanghai) Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
TC-110
TC-110
Phase 2 Clinical
Tcr2 Therapeutics
Lymphoma, Large B-Cell, Diffuse, Primary mediastinal B cell lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04323657
Intervention Type
Drug
Indications
Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute)
4SCAR-19
Phase 2 Clinical
Shenzhen Geno-Immune Medical Institute
Lymphoma, B-Cell
NCT Number
NCT04429438
Intervention Type
Biological
Indications
B Cell Lymphoma (BCL)
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
TAK-007
TAK-007
Phase 2 Clinical
The University Of Texas MD Anderson Cancer Center
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT05020015
Intervention Type
Biological, Drug
Indications
Study Phase
Phase 2
Recruitment Status
Not yet recruiting
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin)
Phase 2 Clinical
The Medical College Of Wisconsin Nonprofit
Neoplasms
NCT Number
NCT04186520
NCT04049383
Intervention Type
Biological
Biological
Indications
Study Phase
Phase 1/Phase 2
Phase 1
Recruitment Status
Recruiting
Recruiting
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing)
Phase 2 Clinical
Southwest Hospital Chongqing
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT02737085
NCT02710149
Intervention Type
Biological
Biological
Indications
Lymphoma, Large B-Cell, Diffuse
Leukemia; Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Recruitment Status
Unknown status
Recruiting
Anti CD19 chimeric antigen receptor T cell therapy (Beijing Boren Hospital)
Phase 2 Clinical
Beijing Boren Hospital
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04325841
NCT04340154
Intervention Type
Biological
Biological
Indications
Acute Lymphoblastic Leukemia, Pediatric; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoid Leukemia
Study Phase
Phase 2
Phase 2
Recruitment Status
Recruiting
Recruiting
CD19 chimeric antigen receptor T cell therapy (Takara Bio)
TBI-1501
Phase 2 Clinical
Memorial Sloan Kettering Cancer Center, Takara Bio Inc
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03155191
Intervention Type
Biological
Indications
Lymphoblastic Leukemia, Acute Adult
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
CRC-01
Phase 2 Clinical
Curocell Inc
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
NCT Number
NCT04836507
Intervention Type
Biological, Drug
Indications
Relapsed Large B-cell Lymphoma; Refractory Large B-cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); Primary Mediastinal Large B-Cell Lymphoma (PMBCL); High-grade B-cell Lymphoma; Transformed Follicular Lymphoma (TFL)
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
JCAR-014
JCAR-014
Phase 2 Clinical
Fred Hutchinson Cancer Research Center, Juno Therapeutics, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT01865617
NCT02706405
NCT01087294
NCT01593696
Intervention Type
Other, Biological
Other, Biological, Drug
Procedure, Biological
Biological
Indications
ALL; B Cell Lymphoma; Leukemia; Large Cell Lymphoma; Non-Hodgkin Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Completed
Active, not recruiting
Recruiting
Completed
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center)
Phase 2 Clinical
The University Of Texas MD Anderson Cancer Center
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04029038
Intervention Type
Biological, Drug
Indications
CD19 Positive; CD22 Positive; Minimal Residual Disease; Progressive Disease; Recurrent B Acute Lymphoblastic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Non-Hodgkin Lymphoma; Refractory B Acute Lymphoblastic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Non-Hodgkin Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Not yet recruiting
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics)
Phase 2 Clinical
Innovative Cellular Therapeutics Co Ltd, Kunming Medical University, Zhejiang University
Leukemia, Leukemia, Lymphoid, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT03118180
NCT04381741
NCT04661020
NCT02813837
Intervention Type
Biological
Biological
Drug
Biological
Indications
Lymphoma
Diffuse Large B-cell Lymphoma
Non-hodgkin Lymphoma,B Cell
Leukemia, B-Cell; Lymphoma, B-Cell
Study Phase
Phase 1/Phase 2
Phase 1
Early Phase 1
N/A
Recruitment Status
Recruiting
Recruiting
Not yet recruiting
Recruiting
ALLO-501
ALLO-501, ALLO-501A
Phase 2 Clinical
Cellectis
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
NCT Number
NCT04416984
NCT03939026
NCT02735083
Intervention Type
Biological, Drug, Genetic
Biological, Drug, Genetic
Biological
Indications
Study Phase
Phase 1/Phase 2
Phase 1
Phase 1
Recruitment Status
Active, not recruiting
Active, not recruiting
Active, not recruiting
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh)
Phase 2 Clinical
National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh
Immunologic Deficiency Syndromes
NCT Number
NCT03330795
Intervention Type
Biological
Indications
Study Phase
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
AUTO-1
AUTO1, AUTO-1
Phase 2 Clinical
University College London
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04404660
NCT02935257
NCT02443831
Intervention Type
Biological
Biological
Procedure, Biological, Drug
Indications
Leukemia, Lymphoblastic, Acute, Lymphoma
Acute Lymphoblastic Leukemia; Burkitt Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Active, not recruiting
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)
Phase 2 Clinical
The First Affiliated Hospital Of Nanchang University
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma
NCT Number
NCT04196205
Intervention Type
Biological
Indications
Acute Lymphoblastic Leukemia ,Lymphomas
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
AUTO-3
AUTO-3
Phase 2 Clinical
University College London
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03289455
Intervention Type
Biological
Indications
B Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Refractory Childhood Acute Lymphoblastic Leukemia; B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1/Phase 2
Recruitment Status
Completed
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital)
Phase 2 Clinical
Shenzhen University General Hospital
Lymphoma, B-Cell
NCT Number
NCT04723914
Intervention Type
Biological
Indications
Lymphoma, B-Cell; Relapse/Recurrence; Refractory Lymphoma; Dual-target CAR-T Cells
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
TAC01-CD19
TAC01-CD19
Phase 2 Clinical
Triumvira Immunologics
Lymphoma, B-Cell
NCT Number
NCT03880279
Intervention Type
Biological
Indications
Lymphoma, B-Cell
Study Phase
Phase 1/Phase 2
Recruitment Status
Not yet recruiting
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology)
Phase 2 Clinical
Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT05020392
NCT03366350
Intervention Type
Drug
Procedure
Indications
Acute Lymphoblastic Leukemia; B Cell Lymphoma
Study Phase
Phase 3
Phase 1/Phase 2
Recruitment Status
Recruiting
Recruiting
BinD-19 (Shenzhen BinDeBio)
BinD-19
Phase 2 Clinical
Shenzhen Bindebio Ltd
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03156101
NCT03265106
Intervention Type
Biological
Biological
Indications
Relapsed B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed／Refractory B-cell Lymphoma
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood; Refractory B-cell Acute Lymphoblastic Leukemia, Childhood; Relapsed/Refractory B-cell Lymphoma, Childhood
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Recruitment Status
Active, not recruiting
Active, not recruiting
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital)
Phase 2 Clinical
People'S Liberation Army General Hospital Military Service
Leukemia, Lymphoma
NCT Number
NCT03185494
Intervention Type
Biological
Indications
Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis); Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Unknown status
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta)
Phase 2 Clinical
University Of Alberta
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03938987
Intervention Type
Biological
Indications
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing)
Phase 2 Clinical
Southwest Hospital Chongqing
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT02349698
Intervention Type
Biological
Indications
Leukemia; Lymphoma
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals)
CARCIK-CD19, CIK-CAR.CD19
Phase 2 Clinical
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD19-CART
Phase 2 Clinical
Hrain Biotechnology Co Ltd
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02685670
NCT02652910
NCT03706547
Intervention Type
Biological, Drug
Drug
Biological, Drug
Indications
Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Multiple Myeloma in Relapse; Multiple Myeloma Progression
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Recruitment Status
Unknown status
Unknown status
Not yet recruiting
U-CART (Shanghai Bioray Laboratory Inc)
Phase 2 Clinical
Bioray Laboraytories Inc
Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03229876
Intervention Type
Biological
Indications
Study Phase
N/A
Recruitment Status
Recruiting
MB-CART2019.1
MB-CART2019.1
Phase 2 Clinical
Miltenyi Biotec
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04844866
NCT04792489
NCT03870945
Intervention Type
Drug, Genetic
Biological
Biological
Indications
B-cell Non Hodgkin Lymphoma
Study Phase
Phase 2
Phase 2
Phase 1/Phase 2
Recruitment Status
Recruiting
Recruiting
Active, not recruiting
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University)
Phase 1 Clinical
Fujian Medical University
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT04215016
Intervention Type
Biological
Indications
Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology)
Phase 1 Clinical
Beijing Yongtai Rec Biotechnology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
RO-7227166
RO-7227166
Phase 1 Clinical
F. Hoffmann-La Roche Ltd
Lymphoma, Non-Hodgkin
NCT Number
NCT04077723
Intervention Type
Drug
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital)
Phase 1 Clinical
Henan Provincial Cancer Hospital
Lymphoma, B-Cell
NCT Number
NCT03881761
Intervention Type
Biological
Indications
B-Cell Lymphoma Stage I; Refractory; Relapsed
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology)
Phase 1 Clinical
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, B-Cell
Murine CD19 CAR-T cell therapy (Yake)
Phase 1 Clinical
Shanghai YaKe Biotechnology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04532281
Intervention Type
Drug
Indications
Acute Lymphoblastic Leukemia; Non-Hodgkin Lymphoma of Soft Tissue
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Humanized CD19 CAR-T cell therapy (Yake)
YK-C19
Phase 1 Clinical
Shanghai YaKe Biotechnology Co Ltd
Lymphoma, B-Cell, Leukemia, Lymphoid
NCT Number
NCT04532268
NCT03564977
Intervention Type
Drug
Biological
Indications
Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma,B Cell
Lymphoma, B-Cell; Leukemia, B-Cell; Minimal Disease, Residual
Study Phase
Early Phase 1
N/A
Recruitment Status
Recruiting
Unknown status
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech)
Phase 1 Clinical
Tianjin Timmune Biotech Inc
Leukemia, Lymphoma, Non-Hodgkin
NCT Number
NCT03910842
Intervention Type
Biological
Indications
Non-Hodgkin Lymphoma of Intestine; Leukemia
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed)
Phase 1 Clinical
Aikangd Biomedical Technology (Suzhou) Co Ltd
Leukemia, Lymphoma
AFM-11
AFM-11
Phase 1 Clinical
Affimed
Leukemia, B-Cell, Lymphoma, Non-Hodgkin
NCT Number
NCT02106091
NCT02848911
Intervention Type
Drug
Drug
Indications
Relapsed B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma
Leukemia, B-Cell
Study Phase
Phase 1
Phase 1
Recruitment Status
Terminated
Terminated
CC-97540
CC-97540
Phase 1 Clinical
Juno Therapeutics
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma
NCT Number
NCT04231747
Intervention Type
Biological
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
UCART-19
S-68587, UCART-19
Phase 1 Clinical
Cellectis
Leukemia, Lymphoid, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02746952
NCT02808442
NCT02735083
Intervention Type
Biological
Biological
Biological
Indications
Study Phase
Phase 1
Phase 1
Phase 1
Recruitment Status
Completed
Completed
Active, not recruiting
ET-019002
ET-019002
Phase 1 Clinical
Eureka Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03642496
Intervention Type
Biological
Indications
B-Cell Malignancies
Study Phase
Early Phase 1
Recruitment Status
Not yet recruiting
CD19 CAR-T (HuaDao CAR-Tcell)
Phase 1 Clinical
Huadao (Shanghai) Biopharma Co Ltd
Lymphoma, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Senl-1904A
Senl-1904A, Senl_1904A
Phase 1 Clinical
Hebei Senlang Biological Technology Co Ltd
Leukemia, Lymphoid, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03840317
Intervention Type
Biological
Indications
Acute Lymphocytic Leukemia
Study Phase
Phase 1
Recruitment Status
Active, not recruiting
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology)
Phase 1 Clinical
Shanghai Longyao Biological Technology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04166838
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia (B-ALL); Safety and Efficacy of CD19 UCAR-T Cells
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Anti-CD19 chimeric antigen receptor T cell therapy (Wuhan Sian Medical Technology)
Phase 1 Clinical
Wuhan Si'an Medical Technology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
GC007g
GC-007G
Phase 1 Clinical
Gracell Biotechnologies (Shanghai) Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04516551
Intervention Type
Biological
Indications
Relapsed Adult ALL; B Cell Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology)
Phase 1 Clinical
Hrain Biotechnology
POEMS Syndrome
NCT Number
NCT03879382
Intervention Type
Biological, Drug
Indications
Study Phase
Phase 1
Recruitment Status
Active, not recruiting
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)
Phase 1 Clinical
The First Affiliated Hospital Of Nanchang University
Multiple Myeloma
NCT Number
NCT04194931
Intervention Type
Biological
Indications
Relapsed or Refractory Multiple Myeloma
Study Phase
Phase 1
Recruitment Status
Recruiting
GC019F
Phase 1 Clinical
Gracell Biotechnologies (Shanghai) Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04595162
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
GC-007F (Gracell Biotechnology)
GC-007F
Phase 1 Clinical
Gracell Biotechnologies (Shanghai) Co Ltd
Lymphoma, B-Cell
NCT Number
NCT03825718
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia
Study Phase
Early Phase 1
Recruitment Status
Recruiting
GC-012F
GC-012F
Phase 1 Clinical
Gracell Biotechnologies (Shanghai) Co Ltd
Multiple Myeloma
NCT Number
NCT04935580
NCT04236011
NCT04617704
NCT04412889
Intervention Type
Biological
Biological
Biological
Biological
Indications
Multiple Myeloma
Study Phase
Phase 1/Phase 2
Early Phase 1
Early Phase 1
Early Phase 1
Recruitment Status
Not yet recruiting
Recruiting
Not yet recruiting
Not yet recruiting
iPD1 CD19 eCAR-T therapy (Marino Biotechnology)
Phase 1 Clinical
Chengdu Yinhe Biomedicine Co Ltd, Beijing Mali Biotechnology Co Ltd
Lymphoma, B-Cell
NCT Number
NCT03208556
Intervention Type
Biological, Drug
Indications
Relapsed or Refractory B-cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Unknown status
CD19 CAR engineered autologous T-cells（Sabz Biomedicals）
Phase 1 Clinical
Leukemia, Biphenotypic, Acute
NCT Number
NCT04653493
Intervention Type
Biological, Drug
Indications
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL); Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University)
Phase 1 Clinical
Kunming Medical University
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04289220
NCT03854994
Intervention Type
Biological
Biological
Indications
B Cell Lymphoma; B-cell Acute Lymphoblastic Leukemia
B Cell Lymphoma; B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University)
Phase 1 Clinical
Shanghai Jiaotong University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03919526
Intervention Type
Biological, Drug
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
FT-819
FT-8198, FT-819
Phase 1 Clinical
Fate Therapeutics
Lymphoma, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04629729
Intervention Type
Drug
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
RPM CD19-mbIL15-CAR-T cell therapy (Eden BioCell)
Phase 1 Clinical
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Primary mediastinal B cell lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04844086
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma, Relapsed; Non-Hodgkin's Lymphoma Refractory; Primary Mediastinal Large B Cell Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; High-grade B-cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering)
Phase 1 Clinical
Institute Of Hematology & Blood Diseases Hospital
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT02975687
NCT03029338
Intervention Type
Biological
Biological
Indications
Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukaemia Recurrent
Lymphomas Non-Hodgkin's B-Cell; Relapse
Study Phase
Phase 1
Phase 1
Recruitment Status
Completed
Active, not recruiting
ICT19G1
ICT-19G1
Phase 1 Clinical
Innovative Cellular Therapeutics Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
RGV-004
RGV-004
Phase 1 Clinical
Hangzhou Rongu Biotechnology Co Ltd
Lymphoma, B-Cell
NCT Number
NCT04887025
Intervention Type
Biological
Indications
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
GNC-038
GNC-038
Phase 1 Clinical
Sichuan Baili Pharmaceutical Co Ltd
Solid tumours, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04606433
Intervention Type
Drug
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell)
Phase 1 Clinical
Immune Cell
Lymphoma, B-Cell, Leukemia, Lymphoid, Leukemia, B-Cell
NCT Number
NCT03383952
Intervention Type
Biological
Indications
B Cell Leukemia; B Cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital)
Phase 1 Clinical
Wuhan Union Hospital
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04796688
Intervention Type
Drug
Indications
Acute Lymphoblastic Leukemia; Chronic Lymphoblastic Leukemia; B-cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
CAR-NK019（Second Affiliated Hospital, School of Medicine, Zhejiang University）
Phase 1 Clinical
Lymphoma, Non-Hodgkin
NCT Number
NCT04887012
Intervention Type
Biological
Indications
B-cell Non Hodgkin Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells
TAK-940
Phase 1 Clinical
Takeda
Neoplasms
NCT Number
NCT04464200
NCT04556266
Intervention Type
Drug
Biological
Indications
Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma; Chronic Lymphocytic Leukemia; Indolent Non-Hodgkin Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia; Burkitt's Lymphoma; Primary CNS Lymphoma
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center)
Phase 1 Clinical
Memorial Sloan Kettering Cancer Center
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03085173
Intervention Type
Biological
Indications
Chronic Lymphocytic Leukemia (CLL); Relapsed; Refractory
Study Phase
Phase 1
Recruitment Status
Active, not recruiting
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine)
Phase 1 Clinical
The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04303520
Intervention Type
Biological, Drug
Indications
CD19-positive ALL
Study Phase
Phase 1
Recruitment Status
Recruiting
TG-1801
NI-1701, TG-1801
Phase 1 Clinical
Novimmune
Lymphoma, B-Cell, Marginal Zone, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04806035
NCT03804996
Intervention Type
Biological
Biological, Drug
Indications
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.)
Phase 1 Clinical
China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital
Lymphoma, B-Cell
NCT Number
NCT03952923
Intervention Type
Biological
Indications
B-cell Malignancy
Study Phase
Phase 1
Recruitment Status
Recruiting
FT-596
FT-596
Phase 1 Clinical
Fate Therapeutics Inc
Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04245722
Intervention Type
Drug
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)
Phase 1 Clinical
Second Affiliated Hospital Of Zhejiang University School Of Medicine
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Primary mediastinal B cell lymphoma
NCT Number
NCT04850560
NCT04833504
Intervention Type
Biological
Biological
Indications
Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma; Transformed Follicular Lymphoma; Primary Mediastinal Large B-cell Lymphoma
Study Phase
Phase 1
N/A
Recruitment Status
Recruiting
Completed
CLBR-001/SWI-019
CLBR-001/
Phase 1 Clinical
California Institute For Biomedical Research, Abbvie Inc
Lymphoma, B-Cell
NCT Number
NCT04488354
Intervention Type
Combination Product
Indications
Relapsed/Refractory B-cell Lymphomas; Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Chronic Lymphocytic Leukemia (CLL); Marginal Zone Lymphoma (MZL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma (SLL); Primary Mediastinal Large B Cell Lymphoma; Transformed Follicular Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech)
LCAR-L10D
Phase 1 Clinical
Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT03593109
NCT04094766
Intervention Type
Drug
Drug
Indications
Refractory B Acute Lymphoblastic Leukemia; Relapse B Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Phase 1
Recruitment Status
Terminated
Withdrawn
CD19-directed T-cell immunotherapy (CRISPR Therapeutics)
CTX-110
Phase 1 Clinical
Crispr Therapeutics
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04035434
Intervention Type
Biological
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
PACE CART-19 cell therapy (University of Pennsylvania)
Phase 1 Clinical
University Of Pennsylvania
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT05037669
Intervention Type
Biological
Indications
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center)
Phase 1 Clinical
Fred Hutchinson Cancer Research Center
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT03103971
Intervention Type
Other, Procedure, Biological, Drug
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19 CAR T-cell therapy (University College London)
4G7-CARD
Phase 1 Clinical
University College London
Lymphoma
NCT Number
NCT04443829
Intervention Type
Biological
Indications
Primary CNS Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19.CAR-VST
CD19.CAR-VST
Phase 1 Clinical
Baylor College Of Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Anti-CD19-CAR T cell therapy (Kecellitics Biotech)
Phase 1 Clinical
Kecellitics Biotech Company Ltd
Leukemia, Lymphoma
NCT Number
NCT04100187
Intervention Type
Biological
Indications
Lymphoma
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University)
Phase 1 Clinical
Stanford University
Lymphoma, B-Cell
NCT Number
NCT03233854
Intervention Type
Other, Biological, Drug
Indications
B Acute Lymphoblastic Leukemia; CD19 Positive; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly; Minimal Residual Disease; Philadelphia Chromosome Positive; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-human CD19-CD22 T cell therapy
Phase 1 Clinical
Hrain Biotechnology Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
PCAR-019 (Anke Biotechnology)
Phase 1 Clinical
Anhui Anke Biotechnology (Group) Co Ltd
Lymphoma, Large B-Cell, Diffuse, Leukemia, Prolymphocytic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02851589
NCT02819583
NCT04184414
NCT04237428
Intervention Type
Biological
Biological
Drug
Biological
Indications
Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; B-cell Prolymphocytic Leukemia; Diffuse Large Cell Lymphoma
Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; B-cell Prolymphocytic Leukemia; Diffuse Large Cell Lymphoma
B Acute Lymphoblastic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma
Non Hodgkin Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Early Phase 1
N/A
Recruitment Status
Unknown status
Unknown status
Recruiting
Recruiting
XYF19 CAR-T cell therapy (Xijing Hospital)
Phase 1 Clinical
The First Affiliated Hospital of Air Force Medical University
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04037566
Intervention Type
Drug, Genetic
Indications
Leukemia Lymphocytic Acute (ALL) in Relapse; Leukemia Lymphocytic Acute (All) Refractory; Lymphoma, B-Cell; CD19 Positive
Study Phase
Phase 1
Recruitment Status
Recruiting
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)
Phase 1 Clinical
Icell Gene Therapeutics
Multiple Myeloma
NCT Number
NCT04162353
Intervention Type
Biological
Indications
Multiple Myeloma in Relapse; Refractory Multiple Myeloma; Plasmacytoid; Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
YTB-323
YTB-323
Phase 1 Clinical
Novartis Pharma Ag
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03960840
Intervention Type
Drug
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
A-319(Evive Biotech)
A-319
Phase 1 Clinical
Evive Biotech Ltd
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04056975
Intervention Type
Biological
Indications
Relapsed or Refractory B-cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
CTA-101
CTA-101
Phase 1 Clinical
Nanjing Bioheng Biotech Co Ltd, Xuzhou Medical University (Xzmu), Nanjing Medical University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04154709
NCT04227015
Intervention Type
Biological
Drug
Indications
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma
Study Phase
Phase 1
Early Phase 1
Recruitment Status
Recruiting
Recruiting
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering)
Phase 1 Clinical
Nagoya University, Shinshu University
Precursor Cell Lymphoblastic Leukemia-Lymphoma
MCM-998
MCM-998, LXG-250
Phase 1 Clinical
Novartis Pharma Ag
Multiple Myeloma
AMG-562
AMG-562
Phase 1 Clinical
Amgen Inc
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular
NCT Number
NCT03571828
Intervention Type
Drug
Indications
Study Phase
Phase 1
Recruitment Status
Active, not recruiting
Virus-specific-CD19.CAR
Phase 1 Clinical
Baylor College Of Medicine
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital)
Phase 1 Clinical
Hebei Yanda Hospital
Lymphoma, B-Cell
NCT Number
NCT04260932
NCT04260945
Intervention Type
Biological
Biological
Indications
B-cell Lymphoma
B-cell Leukemia
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health)
Phase 1 Clinical
Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics)
Phase 1 Clinical
Icell Gene Therapeutics
Lymphoma, B-Cell, Leukemia, Leukemia, B-Cell
NCT Number
NCT04156178
Intervention Type
Biological
Indications
B Cell Lymphoma; B Cell Leukemia
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center)
Phase 1 Clinical
University Hospitals Cleveland Medical Center
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04732845
Intervention Type
Biological, Drug
Indications
Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD22/CD19 monoclonal antibody-toxin conjugate
Phase 1 Clinical
Ut Southwestern Medical Center
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
aCD19z
aCD19z
Phase 1 Clinical
Christie Hospital Nhs Foundation Trust
Lymphoma, Non-Hodgkin
PTG-01
PTG-01
Phase 1 Clinical
Protheragen
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ThisCART-19
ThisCART-19
Phase 1 Clinical
Fundamenta Therapeutics Ltd
Lymphoma, B-Cell
NCT Number
NCT05106907
NCT04384393
Intervention Type
Biological
Biological
Indications
B Cell Malignancy
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
pCAR-19B
Phase 1 Clinical
Chongqing Precision Biotechnology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04888442
NCT04888468
Intervention Type
Biological
Biological
Indications
Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia; Relapsed Pediatric ALL; Refractory Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Phase 1
Recruitment Status
Recruiting
Recruiting
H-31970-SAGAN
H-31970-SAGAN
Phase 1 Clinical
Baylor College Of Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
CD19-CAR
CD19-CAR
Phase 1 Clinical
The University Of Texas MD Anderson Cancer Center
Leukemia, Lymphoma
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center)
Phase 1 Clinical
Uclas Jonsson Comprehensive Cancer Center
Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT04007029
Intervention Type
Biological, Drug
Indications
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics)
Phase 1 Clinical
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04714593
Intervention Type
Biological
Indications
Acute Lymphocytic Leukemia， B-Cell
Study Phase
Phase 1/Phase 2
Recruitment Status
Recruiting
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital)
Phase 1 Clinical
Xinqiao Hospital, Army Medical University
Lymphoma, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04264039
Intervention Type
Biological, Drug
Indications
B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma
Study Phase
Early Phase 1
Recruitment Status
Not yet recruiting
GC-022
GC-022, GC-022F
Phase 1 Clinical
Gracell Biotechnologies (Shanghai) Co Ltd
Leukemia, Lymphoid
NCT Number
NCT04626908
NCT03825731
NCT04412174
NCT04129099
Intervention Type
Drug
Biological
Biological
Biological
Indications
Relapsed and Refractory; Lymphoid Hematological Malignancies
B-cell Acute Lymphoblastic Leukemia
B-cell Non Hodgkin Lymphoma
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1/Phase 2
Early Phase 1
Early Phase 1
Early Phase 1
Recruitment Status
Not yet recruiting
Recruiting
Not yet recruiting
Recruiting
CD19/CD20 CAR-T Cell Therapy (PersonGen)
Phase 1 Clinical
NCT Number
NCT04700319
Intervention Type
Drug
Indications
CAR
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Anti-BCMA/CD19 CAR-T（Autolus）
Phase 1 Clinical
Multiple Myeloma
NCT Number
NCT04795882
Intervention Type
Biological
Indications
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology)
Phase 1 Clinical
Hrain Biotechnology
Leukemia, Lymphoid
Anti-CD19 redirected NK cell therapy (National University Health System, Singapore)
Phase 1 Clinical
National University Health System
Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT01974479
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Suspended
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology)
Phase 1 Clinical
Tianjin Mycure Medical Technology Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03671460
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center)
Phase 1 Clinical
City Of Hope National Medical Center
Lymphoma, Non-Hodgkin
BZ019
BZ-019
Phase 1 Clinical
Shanghai Cell Therapy Research Institute
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Primary mediastinal B cell lymphoma, Lymphoma, Follicular
NCT Number
NCT04067414
NCT04250324
Intervention Type
Biological
Biological
Indications
Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Transformed Lymphoma; Primary Mediastinal Large B Cell Lymphoma
Large B-cell Lymphoma
Study Phase
Phase 1
Phase 1
Recruitment Status
Active, not recruiting
Recruiting
4-1BBz CD19-Her2tG (Seattle Children's Hospital)
Phase 1 Clinical
Seattle Children'S Hospital
Neoplasms
CD19 CARvac T cell therapy (iCell Gene Therapeutics)
Phase 1 Clinical
Icell Gene Therapeutics
Lymphoma, B-Cell, Leukemia, B-Cell
NCT Number
NCT04156243
Intervention Type
Biological
Indications
B Cell Lymphoma; B Cell Leukemia
Study Phase
Early Phase 1
Recruitment Status
Recruiting
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech)
Phase 1 Clinical
China Immunotech Co Ltd
Lymphoma, Non-Hodgkin
NCT Number
NCT04697290
Intervention Type
Biological
Indications
B-cell Non-Hodgkin's Lymphoma
Study Phase
Early Phase 1
Recruitment Status
Not yet recruiting
PBLTT52CAR19
Phase 1 Clinical
Great Ormond Street Hospital For Children Nhs Foundation Trust
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT04557436
Intervention Type
Drug
Indications
B Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Recruiting
MC-19PD1 CAR-T cell therapy (Peking University)
Phase 1 Clinical
Peking University
Lymphoma, B-Cell
NCT Number
NCT03932955
Intervention Type
Biological
Indications
Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
CD19-STAR-T cell therapy (China Immunotech Co., Ltd.)
Phase 1 Clinical
Hebei Yanda Hospital, China Immunotech Co Ltd
Lymphoma, B-Cell
NCT Number
NCT03953599
Intervention Type
Biological
Indications
B Cell Malignancy
Study Phase
Phase 1
Recruitment Status
Recruiting
CTA-30X
CTA30X, CTA-30X
Phase 1 Clinical
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04689204
Intervention Type
Drug
Indications
Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma
Study Phase
Early Phase 1
Recruitment Status
Recruiting
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research)
WZTL002-1
Phase 1 Clinical
The Malaghan Institute Of Medical Research
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Primary mediastinal B cell lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT04049513
Intervention Type
Biological, Drug
Indications
Lymphomas Non-Hodgkin's B-Cell; Diffuse Large B-cell Lymphoma (DLBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Transformed Follicular Lymphoma (TFL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL)
Study Phase
Phase 1
Recruitment Status
Recruiting
Duvortuxizumab
MGD-011, JNJ-64052781
Phase 1 Clinical
Macrogenics
Hematologic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT02454270
NCT02743546
Intervention Type
Drug
Drug
Indications
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell
Study Phase
Phase 1
Phase 1
Recruitment Status
Terminated
Withdrawn
CD19x22 CAR T Cell Therapy (University Of Colorado Denver)
Phase 1 Clinical
University Of Colorado, Denver, Usa
Lymphoma, Non-Hodgkin
NCT Number
NCT05098613
Intervention Type
Drug
Indications
Study Phase
Phase 1
Recruitment Status
Not yet recruiting
K-193
K-193
Phase 1 Clinical
Beijing Lvzhu Biological Technology Co Ltd
Lymphoma, B-Cell
Anti-CD19 CAR-T cell therapy (Juno Therapeutics)
Phase 1 Clinical
Juno Therapeutics
Hematologic Neoplasms
NCT Number
NCT03085173
Intervention Type
Biological
Indications
Chronic Lymphocytic Leukemia (CLL); Relapsed; Refractory
Study Phase
Phase 1
Recruitment Status
Active, not recruiting
ET190L1-ARTEMIS T cells (Eureka Therapeutics)
ET190, ET-190, ET190L1, ET190L1-ARTEMI
Phase 1 Clinical
Eureka Therapeutics
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT03415399
NCT03379493
NCT03895944
Intervention Type
Biological
Biological
Biological
Indications
Lymphoma, B-Cell
Lymphomas Non-Hodgkin's B-Cell
CD19+ Lymphoma, B-Cell; CD19+ Leukemia, B-Cell
Study Phase
Phase 1
Phase 1
Early Phase 1
Recruitment Status
Completed
Terminated
Recruiting
GB5005 chimeric antigen receptor T cell therapy (Genbase)
Phase 1 Clinical
Shanghai Genbase Biotechnology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University)
Phase 1 Clinical
Zhejiang University
Multiple Myeloma
NCT Number
NCT05085444
NCT05085418
NCT05085431
NCT04603872
NCT05030779
Intervention Type
Biological
Biological
Biological
Drug
Biological
Indications
Multiple Myeloma in Relapse; Multiple Myeloma, Refractory; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphocytic Leukaemia Refractory; Non-Hodgkin's Lymphoma, Relapsed; Non-Hodgkin's Lymphoma Refractory
Study Phase
Early Phase 1
Early Phase 1
Early Phase 1
Early Phase 1
Early Phase 1
Recruitment Status
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University)
Phase 1 Clinical
First Affiliated Hospital Of Zhejiang University
Lymphoma, Large B-Cell, Diffuse
NCT Number
NCT04486872
Intervention Type
Biological
Indications
Diffuse Large B Cell Lymphoma
Study Phase
Phase 1
Recruitment Status
Recruiting
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital)
Phase 1 Clinical
Seattle Children'S Hospital
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 CAR-T cell therapy (Bioceltech)
Clinical
Bioceltech Therapeutics Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03574168
Intervention Type
Biological
Indications
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1
Recruitment Status
Unknown status
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology)
Clinical
Nanjing Kati Medical Technology Co Ltd
Neoplasms
4G7SDIE
Clinical
Synimmune, The University Of Tubingen
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology)
Clinical
Hebei Senlang Biological Technology Co Ltd
Leukemia
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies)
PZ-01
Clinical
Pinze Lifetechnology
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research)
Clinical
Leidos
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
因诺卡替-19细胞
IND
Shenzhen Inno Immunization Co Ltd
Leukemia, Lymphoid
ICTCAR003
ICTCAR003
IND
Innovative Cellular Therapeutics Co Ltd
Leukemia, Biphenotypic, Acute
Chimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene)
BG-19, BG-19C, BG-T19
IND
Guangzhou Bio-Gene Technology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
CD19-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology)
IND
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Lymphoma
GC-502
GC502
Preclinical
Gracell Biotechnologies (Shanghai) Co Ltd
Lymphoma, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
EBV-CTL (Atara/MSKCC)
EBV-CTL-Atara-MSKCC
Preclinical
Memorial Sloan Kettering Cancer Center
Lymphoproliferative Disorders
aT19
Preclinical
Beijing Yongtai Immune Applied Science And Technology Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CAR-T-19-DNR
CAR-T-19-DNR
Preclinical
Beijing Yongtai Immune Applied Science And Technology Co Ltd
Lymphoma, Non-Hodgkin
Nex-G
Nex-G
Preclinical
Suzhou Yaomingjunuo Biotechnology Co Ltd
Lymphoma, Non-Hodgkin
OnCARlytics(Imugene)
CF-33-CD-19
Preclinical
City Of Hope National Medical Center
Solid tumours
UBG-T19
Preclinical
Guangzhou Bio-Gene Technology Co Ltd
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
AB-202 (Artiva Biotherapeutics)
Preclinical
Artiva Biotherapeutics Inc
Neoplasms
LCAR-AIO
LCAR-AIO
Preclinical
Nanjing Legend Biotechnology Co Ltd
Lymphoma, Large B-Cell, Diffuse
CMG1A46
CMG1A-46, CMG1A46
Preclinical
Neoplasms
LCB-73
LCB-73
Preclinical
Legochem Biosciences
HY-004 (Juventas)
HY-004 (Juventas)
Preclinical
Heyuan Biotechnology (Tianjin) Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
IKS-03
IKS-03
Preclinical
Iksuda Therapeutics
Lymphoma, B-Cell
B-193
B-193
Preclinical
Shanghai Yanyi Biological Technology Co Ltd
Neoplasms
LQ-030
LQ-030, LQ030
Preclinical
Leukemia, Biphenotypic, Acute
HY-003
HY-003
Preclinical
Heyuan Biotechnology (Tianjin) Co Ltd
CD19/CD3
Preclinical
Wuhan Yzy Biopharma Co Ltd
Lymphoma
GC-198
GC198
Preclinical
Gracell Biotechnologies (Shanghai) Co Ltd
Lymphoma, B-Cell
RD-301
Preclinical
Nanjing Iaso Biotherapeutics Co Ltd
Precursor Cell Lymphoblastic Leukemia-Lymphoma
C-CAR011
Pending
Pla General Hospital
Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT02081937
NCT03299738
NCT03154775
NCT03018093
NCT02976857
NCT03327285
NCT01864889
Intervention Type
Biological
Biological
Biological
Biological
Biological
Biological
Biological
Indications
Hematopoietic/Lymphoid Cancer; Non-hodgkin Lymphoma,B Cell; Mantle Cell Lymphoma
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
Refractory or Relapsed Non-Hodgkin Lymphoma
Relapsed or Refractory Acute Lymphoblastic Leukemia
Refractory Diffuse Large B-Cell Lymphoma
Acute Lymphoblastic Leukemia(ALL)
Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Study Phase
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
Recruitment Status
Unknown status
Unknown status
Unknown status
Unknown status
Completed
Active, not recruiting
Unknown status
MDX 1342
MDX-1342
Pending
Medarex
Arthritis, Rheumatoid, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT00639834
NCT00593944
Intervention Type
Biological
Biological
Indications
Rheumatoid Arthritis
Chronic Lymphocytic Leukemia
Study Phase
Phase 1
Phase 1
Recruitment Status
Completed
Completed
PF-6883541
PF-6883541, PF-06883541
Pending
Pfizer Pharmaceuticals Ltd (China)
Neoplasms
Anti-CD3-anti-CD19 bispecific monoclonal antibody (Nonindustrial source)
Pending
Nonindustrial Source
Lymphoma, Non-Hodgkin
CD19 CAR-T cell (Pregene)
Pending
Shenzhen Prekin Biopharmaceutical Co Ltd
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NCT Number
NCT03146533
NCT03263208
NCT03101709
NCT03685786
NCT02924753
Intervention Type
Biological, Drug
Biological, Drug
Biological, Drug
Biological
Biological, Drug
Indications
B Cell Lymphoma
B-cell Acute Lymphocytic Leukemia
B Cell Lymphoma
Leukemia, Lymphocytic, Acute, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell
B-cell Acute Lymphoblastic Leukemia
Study Phase
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruitment Status
Unknown status
Unknown status
Unknown status
Recruiting
Unknown status
Modified anti-CD19 T-cell therapy (Fred Hutchinson Cancer Research Center)
Pending
Fred Hutchinson Cancer Research Center
Neoplasms
DI-B4
DI-B4
Pending
Merck Serono, Cancer Research Uk
Lymphoma, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
NCT Number
NCT01805375
Intervention Type
Drug
Indications
Indolent B-cell Lymphoma; Chronic Lymphocytic Leukaemia; Waldenström Macroglobulinaemia
Study Phase
Phase 1
Recruitment Status
Completed
Denintuzumab mafodotin
SGN-19A, SGN-CD19A
Discontinued
Seattle Genetics Inc
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT02592876
NCT02855359
NCT01786135
NCT01786096
Intervention Type
Drug
Drug
Drug
Drug
Indications
Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular, Grade 3b; Follicular Lymphoma, Grade 3b
Diffuse, Large B-Cell, Lymphoma; Follicular Lymphoma, Grade 3b; Transformed Lymphoma / DLBCL
Burkitt Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Study Phase
Phase 2
Phase 2
Phase 1
Phase 1
Recruitment Status
Terminated
Terminated
Completed
Completed
19-28z+
19-28z+
Discontinued
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute
Leukemia
Oncolysin B
Discontinued
Immunogen
Leukemia, Lymphoma, Lymphoma, Non-Hodgkin
CD19-specific T-cell therapy (B cell malignancies), Christie NHS Foundation Trust
Discontinued
The University Of Manchester, Cancer Research Uk, Christie Hospital Nhs Foundation Trust
Lymphoma, Non-Hodgkin
NCT Number
NCT01493453
Intervention Type
Genetic
Indications
CD19 Positive Non-Hodgkin Lymphoma
Study Phase
Phase 1
Recruitment Status
Unknown status
FH-2494
FH-2494
Discontinued
Fred Hutchinson Cancer Research Center, National Cancer Institute
Lymphoma, B-Cell, Marginal Zone, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
CD19CAR
CD19CAR
Discontinued
National Cancer Institute, City Of Hope National Medical Center
Leukemia, Hairy Cell, Lymphomatoid Granulomatosis, Lymphoma
NCT Number
NCT04160195
Intervention Type
Biological, Drug
Indications
Study Phase
Phase 1
Recruitment Status
Completed
Taplitumomab paptox
Discontinued
University Of Minnesota
Leukemia
SGN-CD19B
SGN-CD19B
Discontinued
Seattle Genetics Inc
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
NCT Number
NCT02702141
Intervention Type
Drug
Indications
Non-Hodgkin Lymphoma; DLBCL; Diffuse Large B-cell Lymphoma; Grade 3 Follicular Lymphoma
Study Phase
Phase 1
Recruitment Status
Terminated
Monoclonal antibody B43 Genistein-conjugate
Discontinued
University Of Minnesota, Bristol-Myers Squibb Company
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
NCT Number
NCT00004858
Intervention Type
Biological
Indications
Leukemia; Lymphoma
Study Phase
Phase 1
Recruitment Status
Unknown status
References
Title
Authors
Source
Regulatory role of CD19 molecules in B-cell activation and differentiation
de Rie M.A., Schumacher T.N., van Schijndel G.M., van Lier R.A., Miedema F.,
Cell. Immunol. 118:368-381(1989)
Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19
Matsumoto A.K., Kopicky-Burd J., Carter R.H., Tuveson D.A., Tedder T.F., Fearon D.T.,
J. Exp. Med. 173:55-64(1991)
CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail
Stamenkovic I., Seed B.,
J. Exp. Med. 168:1205-1210(1988)
Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily
Tedder T.F., Isaacs C.M.,
J. Immunol. 143:712-717(1989)
The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP
Kozmik Z., Wang S., Doerfler P., Adams B., Busslinger M.,
Mol. Cell. Biol. 12:2662-2672(1992)
Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes
Zhou L.J., Ord D.C., Omori S.A., Tedder T.F.,
Immunogenetics 35:102-111(1992)
Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese
Kuroki K., Tsuchiya N., Tsao B.P., Grossman J.M., Fukazawa T., Hagiwara K., Kano H., Takazoe M., Iwata T., Hashimoto H., Tokunaga K.,
Genes Immun. 3:S21-S30(2002)
Complete sequencing and characterization of 21,243 full-length human cDNAs
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Sugano S.,
Nat. Genet. 36:40-45(2004)
The sequence and analysis of duplication-rich human chromosome 16
Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Pennacchio L.A.,
Nature 432:988-994(2004)
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)
The MGC Project Team,
Genome Res. 14:2121-2127(2004)
The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules
Bradbury L.E., Kansas G.S., Levy S., Evans R.L., Tedder T.F.,
J. Immunol. 149:2841-2850(1992)
CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes
Carter R.H., Fearon D.T.,
Science 256:105-107(1992)
CD19 is a substrate of the antigen receptor-associated protein tyrosine kinase in human B cells
Roifman C.M., Ke S.,
Biochem. Biophys. Res. Commun. 194:222-225(1993)
Tyrosine phosphorylation of CD19 in pre-B and mature B cells
Chalupny N.J., Kanner S.B., Schieven G.L., Wee S., Gilliland L.K., Aruffo A., Ledbetter J.A.,
EMBO J. 12:2691-2696(1993)
CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase
Tuveson D.A., Carter R.H., Soltoff S.P., Fearon D.T.,
Science 260:986-989(1993)
Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization
Buhl A.M., Pleiman C.M., Rickert R.C., Cambier J.C.,
J. Exp. Med. 186:1897-1910(1997)
Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 complex requires the cytoplasmic domain of CD19
Sato S., Miller A.S., Howard M.C., Tedder T.F.,
J. Immunol. 159:3278-3287(1997)
Systematic analysis of the role of CD19 cytoplasmic tyrosines in enhancement of activation in Daudi human B cells: clustering of phospholipase C and Vav and of Grb2 and Sos with different CD19 tyrosines
Brooks S.R., Li X., Volanakis E.J., Carter R.H.,
J. Immunol. 164:3123-3131(2000)
The physiologic role of CD19 cytoplasmic tyrosines
Wang Y., Brooks S.R., Li X., Anzelon A.N., Rickert R.C., Carter R.H.,
Immunity 17:501-514(2002)
Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments
Shoham T., Rajapaksa R., Kuo C.C., Haimovich J., Levy S.,
Mol. Cell. Biol. 26:1373-1385(2006)
An antibody-deficiency syndrome due to mutations in the CD19 gene
van Zelm M.C., Reisli I., van der Burg M., Castano D., van Noesel C.J.M., van Tol M.J.D., Woellner C., Grimbacher B., Patino P.J., van Dongen J.J.M., Franco J.L.,
N. Engl. J. Med. 354:1901-1912(2006)
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.,
Science 316:1160-1166(2007)
Crystal structure of B-cell co-receptor CD19 in complex with antibody B43 reveals an unexpected fold
Teplyakov A., Obmolova G., Luo J., Gilliland G.L.,
Proteins 86:495-500(2018)